| Item |
Information |
|
Drug Groups
|
illicit; approved |
|
Description
|
Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. [Wikipedia] |
| Indication |
Used for short-term hypnotic therapy in the management of insomnia for periods of up to one week in duration; however, this medication generally has been replaced by other sedative-hypnotic agents. |
| Pharmacology |
Ethchlorvynol is a sedative drug and schedule IV (USA) controlled substance. It produces cerebral depression, however the exact mechanism of action is not known. |
| Toxicity |
Symptoms of overdose include thrombocytopenia. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
About 90% of a dose is metabolized in the liver. Some ethchlorvynol may also be metabolized in the kidneys. Ethchlorvynol and metabolites undergo extensive enterohepatic recirculation. |
| Absorption |
Rapidly absorbed from gastrointestinal tract. |
| Half Life |
Plasma half-life is approximately 10 to 20 hours, terminal half-life is 21-100 hours. |
| Protein Binding |
35-50% |
| External Links |
|